chr8-119732046-T-G
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_003184.4(TAF2):c.3478A>C(p.Lys1160Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000223 in 1,613,942 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_003184.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TAF2 | ENST00000378164.7 | c.3478A>C | p.Lys1160Gln | missense_variant | Exon 26 of 26 | 1 | NM_003184.4 | ENSP00000367406.2 | ||
TAF2 | ENST00000686879.1 | c.3634A>C | p.Lys1212Gln | missense_variant | Exon 27 of 27 | ENSP00000509206.1 | ||||
TAF2 | ENST00000685235.1 | c.3523A>C | p.Lys1175Gln | missense_variant | Exon 26 of 26 | ENSP00000510174.1 | ||||
TAF2 | ENST00000688645.1 | c.3367A>C | p.Lys1123Gln | missense_variant | Exon 25 of 25 | ENSP00000509978.1 | ||||
TAF2 | ENST00000523904.2 | c.3364A>C | p.Lys1122Gln | missense_variant | Exon 25 of 25 | 3 | ENSP00000430832.2 | |||
TAF2 | ENST00000690144 | c.*609A>C | 3_prime_UTR_variant | Exon 26 of 26 | ENSP00000510548.1 | |||||
TAF2 | ENST00000685202.1 | n.*1003A>C | non_coding_transcript_exon_variant | Exon 27 of 27 | ENSP00000509214.1 | |||||
TAF2 | ENST00000685503.1 | n.*2870A>C | non_coding_transcript_exon_variant | Exon 26 of 26 | ENSP00000509198.1 | |||||
TAF2 | ENST00000685663.1 | n.*3350A>C | non_coding_transcript_exon_variant | Exon 28 of 28 | ENSP00000508988.1 | |||||
TAF2 | ENST00000685684.1 | n.*4945A>C | non_coding_transcript_exon_variant | Exon 25 of 25 | ENSP00000509441.1 | |||||
TAF2 | ENST00000685824.1 | n.*3179A>C | non_coding_transcript_exon_variant | Exon 24 of 24 | ENSP00000510262.1 | |||||
TAF2 | ENST00000685876.1 | n.*3196A>C | non_coding_transcript_exon_variant | Exon 27 of 27 | ENSP00000510493.1 | |||||
TAF2 | ENST00000685993.1 | n.*3293A>C | non_coding_transcript_exon_variant | Exon 25 of 25 | ENSP00000510102.1 | |||||
TAF2 | ENST00000686098.1 | n.*2123A>C | non_coding_transcript_exon_variant | Exon 25 of 25 | ENSP00000509102.1 | |||||
TAF2 | ENST00000688037.1 | n.*2897A>C | non_coding_transcript_exon_variant | Exon 23 of 23 | ENSP00000510169.1 | |||||
TAF2 | ENST00000689919.1 | n.*3085A>C | non_coding_transcript_exon_variant | Exon 26 of 26 | ENSP00000510768.1 | |||||
TAF2 | ENST00000690808.1 | n.*2714A>C | non_coding_transcript_exon_variant | Exon 26 of 26 | ENSP00000509791.1 | |||||
TAF2 | ENST00000690922.1 | n.*1890A>C | non_coding_transcript_exon_variant | Exon 26 of 26 | ENSP00000509498.1 | |||||
TAF2 | ENST00000691880.1 | n.*3134A>C | non_coding_transcript_exon_variant | Exon 25 of 25 | ENSP00000508515.1 | |||||
TAF2 | ENST00000692518.1 | n.*3344A>C | non_coding_transcript_exon_variant | Exon 25 of 25 | ENSP00000508959.1 | |||||
TAF2 | ENST00000692707.1 | n.*3346A>C | non_coding_transcript_exon_variant | Exon 28 of 28 | ENSP00000509024.1 | |||||
TAF2 | ENST00000692916.1 | n.*2865A>C | non_coding_transcript_exon_variant | Exon 25 of 25 | ENSP00000509603.1 | |||||
TAF2 | ENST00000685202.1 | n.*1003A>C | 3_prime_UTR_variant | Exon 27 of 27 | ENSP00000509214.1 | |||||
TAF2 | ENST00000685503.1 | n.*2870A>C | 3_prime_UTR_variant | Exon 26 of 26 | ENSP00000509198.1 | |||||
TAF2 | ENST00000685663.1 | n.*3350A>C | 3_prime_UTR_variant | Exon 28 of 28 | ENSP00000508988.1 | |||||
TAF2 | ENST00000685684.1 | n.*4945A>C | 3_prime_UTR_variant | Exon 25 of 25 | ENSP00000509441.1 | |||||
TAF2 | ENST00000685824.1 | n.*3179A>C | 3_prime_UTR_variant | Exon 24 of 24 | ENSP00000510262.1 | |||||
TAF2 | ENST00000685876.1 | n.*3196A>C | 3_prime_UTR_variant | Exon 27 of 27 | ENSP00000510493.1 | |||||
TAF2 | ENST00000685993.1 | n.*3293A>C | 3_prime_UTR_variant | Exon 25 of 25 | ENSP00000510102.1 | |||||
TAF2 | ENST00000686098.1 | n.*2123A>C | 3_prime_UTR_variant | Exon 25 of 25 | ENSP00000509102.1 | |||||
TAF2 | ENST00000688037.1 | n.*2897A>C | 3_prime_UTR_variant | Exon 23 of 23 | ENSP00000510169.1 | |||||
TAF2 | ENST00000689919.1 | n.*3085A>C | 3_prime_UTR_variant | Exon 26 of 26 | ENSP00000510768.1 | |||||
TAF2 | ENST00000690808.1 | n.*2714A>C | 3_prime_UTR_variant | Exon 26 of 26 | ENSP00000509791.1 | |||||
TAF2 | ENST00000690922.1 | n.*1890A>C | 3_prime_UTR_variant | Exon 26 of 26 | ENSP00000509498.1 | |||||
TAF2 | ENST00000691880.1 | n.*3134A>C | 3_prime_UTR_variant | Exon 25 of 25 | ENSP00000508515.1 | |||||
TAF2 | ENST00000692518.1 | n.*3344A>C | 3_prime_UTR_variant | Exon 25 of 25 | ENSP00000508959.1 | |||||
TAF2 | ENST00000692707.1 | n.*3346A>C | 3_prime_UTR_variant | Exon 28 of 28 | ENSP00000509024.1 | |||||
TAF2 | ENST00000692916.1 | n.*2865A>C | 3_prime_UTR_variant | Exon 25 of 25 | ENSP00000509603.1 | |||||
TAF2 | ENST00000689164.1 | n.*4096A>C | downstream_gene_variant | ENSP00000508729.1 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152194Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000358 AC: 9AN: 251348Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135820
GnomAD4 exome AF: 0.0000198 AC: 29AN: 1461748Hom.: 0 Cov.: 31 AF XY: 0.0000275 AC XY: 20AN XY: 727178
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152194Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74364
ClinVar
Submissions by phenotype
not specified Uncertain:1
- -
Inborn genetic diseases Uncertain:1
The c.3478A>C (p.K1160Q) alteration is located in exon 26 (coding exon 26) of the TAF2 gene. This alteration results from a A to C substitution at nucleotide position 3478, causing the lysine (K) at amino acid position 1160 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
not provided Uncertain:1
ClinVar contains an entry for this variant (Variation ID: 436939). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with TAF2-related conditions. This variant is present in population databases (rs755785500, gnomAD 0.03%). This sequence change replaces lysine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1160 of the TAF2 protein (p.Lys1160Gln). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at